Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Jesser, C, L Mucci, D Farmer, C Moon, H Li, J M Gaziano, M Stampfer, J Ma, and P Kantoff. 2008. "Effects of G/A Polymorphism, rs266882, in the Androgen Response Element 1 of the PSA Gene on Prostate Cancer Risk, Survival and Circulating PSA Levels." British Journal of Cancer 99 (10): 1743–47. https://doi.org/10.1038/sj.bjc.6604690.

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292868

Terms of Use
This article was downloaded from Harvard University’s DASH repository, WARNING: This file should NOT have been available for downloading from Harvard University’s DASH repository.
Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels

Prostate-specific antigen (PSA) is a protease produced in the prostate that cleaves insulin-like growth factor binding protein-3 and other proteins. Production is mediated by the androgen receptor (AR) binding to the androgen response elements (ARE) in the promoter region of the PSA gene. Studies of a single nucleotide polymorphism (PSA – 158 G/A, rs266882) in ARE1 of the PSA gene have been conflicting for risk of prostate cancer and effect on plasma PSA levels. In this nested case–control analysis of 500 white cases and 676 age- and smoking-matched white controls in the Physicians’ Health Study we evaluated the association of rs266882 with risk and survival of prostate cancer and prediagnostic total and free PSA plasma levels, alone or in combination with AR CAG repeats. We used conditional logistic regression, linear regression and Cox regression, and found no significant associations between rs266882 (GG allele vs AA allele) and overall prostate cancer risk (RR = 1.21, 95% confidence intervals (CI): 0.88–1.67) or prostate cancer-specific survival (RR = 0.94, 95% CI: 0.56–1.58). Similarly, no associations were found among high grade or advanced stage tumours, or by calendar year of diagnosis. There was no significant association between rs266882 and baseline total or free PSA levels or the AR CAG repeats, nor any interaction associated with prostate cancer risk. Meta-analysis of 12 studies of rs266882 and overall prostate cancer risk was null.

Prostate-specific antigen (PSA) is a protease produced primarily in the prostate and has widely been used as a diagnostic marker of prostate cancer since the early 1990s (Cohen et al, 1994). Production of PSA is mediated through binding of the androgen receptor (AR) to androgen response elements (ARE) in the promoter region of the PSA gene (Janne et al, 1993). Given the importance of PSA as a prostate cancer biomarker, regulation of the gene is of great interest.

A single nucleotide polymorphism in ARE1 (PSA – 158 G/A) of the PSA gene (rs266882), identified in 1999 (Rao and Cramer, 1999), has been the focus of numerous studies of prostate cancer risk. ARE1 is the primary binding site in the promoter of the PSA gene, and the A to G substitution of rs266882 may affect the binding affinity of the AR and subsequently affect transcript levels of the PSA gene.

An initial case–control study found that men with the homozygous variant GG genotype were at increased risk of advanced prostate cancer (Xue et al, 2000). Subsequent studies on this polymorphism have been conflicting, however, with some reporting an increased risk of prostate cancer or higher PSA levels associated with the G allele (Chiang et al, 2004; Binnie et al, 2005; Schatzl et al, 2005), increased risk with the A allele (Gsur et al, 2002; Medeiros et al, 2002; Lai et al, 2007) or no association with risk (Xu et al, 2002; Rao et al, 2003; Wang et al, 2003; Severi et al, 2006; Sieh et al, 2006). Among healthy men, the AA genotype was associated with higher serum PSA levels compared with those carrying a G allele (Xue et al, 2001). Moreover, the effect of the variant differed as a function of CAG repeat length in the AR gene (Xue et al, 2001). However, the finding with the G/A variant and PSA levels has not been confirmed (Severi et al, 2006). The one study that examined the polymorphism with prostate cancer survival found no significant association with cancer-specific mortality (Severi et al, 2006).

To address the disparity of findings of this SNP, we performed a large nested case–control study in the Physicians’ Health Study (PHS) to evaluate the rs266882 polymorphism in prostate cancer. We examined associations with risk, survival and prediagnostic baseline plasma PSA levels, alone and in combination with AR CAG repeats. Additionally, we performed a meta-analysis of published studies that have examined the rs266882 polymorphism and overall prostate cancer risk.
MATERIALS AND METHODS

Study population

The PHS is a randomised double-blind trial of aspirin and \(\beta\)-carotene among 22,071 US male physicians, aged 40–84 years in 1982; none had a cancer diagnosis at baseline (1989). The current study was nested among the subset of 14,916 participants, who provided plasma and whole blood prior to randomisation. Men were followed for incident cancer, including prostate, and all cases are confirmed through medical record review. Men with prostate cancer are followed to collect detailed information on disease progression and development of metastases. Cause of death is confirmed by review of death certificate and pertinent medical records. Collection of additional study characteristics including age at enrolment, blood collection and processing, stage classification and clinical follow-up were described earlier (Gann et al., 1996).

We included in the study 500 cases diagnosed through 1995. Cases were matched (1:1, 1:2 or 1:3) on age (±1 year when feasible, but up to ±5 years for older men) and smoking status (current, former and never) to controls selected at random from among men free from diagnosed prostate cancer at the time the case was diagnosed. A total of 676 controls were included. All men provided informed consent, and the protocol was approved by the Institutional Review Board at Partners Healthcare.

Laboratory analysis

Using baseline plasma samples, we measured total and free PSA levels by a double-antibody radioimmunoassay using rabbit polyclonal anti-PSA on the basis of competitive binding as described earlier (Gann et al., 1995). The rs266882 polymorphism was assayed on extracted DNA according to the protocol described by Xue et al. (2000). Briefly, the alleles of the G/A polymorphism at position −158 in the promoter region of the PSA gene were amplified and the three possible genotypes were distinguished by cutting with the Nhel restriction enzyme. The AR gene CAG repeat length was determined by running the PCR-amplified fragments on a denaturing polyacrylamide gel with automated fluorescence detection of the fragments and sizing by Genescan (Giovannucci et al., 1997).

Statistical analysis

To limit the potential for population stratification, we restricted the analysis to white men (94% of PHS cohort is white). Hardy–Weinberg equilibrium of allelic frequency was tested by a goodness of fit \(\chi^2\)-test. We calculated odds ratios as an estimate of relative risk ratios and 95% confidence intervals (CI) using conditional logistic regression, matched on age and smoking status, to evaluate the association between the rs266882 polymorphism and prostate cancer risk. We stratified the analysis further according to tumour grade (low grade: Gleason 2–6 or well differentiated; moderate grade: Gleason 7 or moderately differentiated; high grade: Gleason 8–10 or poorly differentiated), stage (T1/T2 or T3/T4) and calendar year of diagnosis (1982–1992 or 1992–1995). The following number of cases and matched controls (cases; controls) for each subgroup: low grade (265; 360), moderate grade (137; 180), high grade (83; 113), localized: T1/T2 (303; 409), or advanced: T3/T4 (156; 214) tumour stage, diagnosed 1982–1992 (357; 530) and diagnosed 1992–1995 (143; 146).

Additionally, we assessed whether the association of rs266882 genotype and prostate cancer risk differed according to categorical pre-diagnostic PSA levels (total PSA: <4 ng ml\(^{-1}\), ≥4 ng ml\(^{-1}\); free PSA: <15%, 15–24%, ≥25%) or number of AR CAG repeats (tertiles, 7–20, 21–23 and 24–39) using likelihood ratio tests.

We used time to event analyses to evaluate the rs266882 polymorphism and cancer-specific survival. Person–time was calculated from date of cancer diagnosis to prostate cancer death or censored at time of death from other causes or end of follow-up (31 March 2007). We used Cox proportional hazard models to calculate hazard ratios and 95% CI, adjusted for aggressive disease (i.e., stage T3/T4 or high grade), age at diagnosis and date of diagnosis (pre/post 1992).

Linear regression was used to estimate the association among PSA levels (natural log transformed) with rs266882 genotype, separately for cases and controls. An interaction with AR CAG repeats was evaluated to determine if the effect of rs266882 genotype differed according to AR CAG repeat length. The SAS Statistical Software (Version 9.1) was used for these analyses.

We conducted a meta-analysis of 12 published studies that have evaluated the association between the rs266882 polymorphism and prostate cancer risk (Xue et al., 2000; Gsur et al., 2004; Medeiros et al., 2002; Wang et al., 2003; Chiang et al., 2004; Binnie et al., 2005; Cicek et al., 2005; Salinas et al., 2005; Severi et al., 2006; Sieh et al., 2006; Lai et al., 2007). To standardise comparisons across the studies, we calculated odds ratios and overall prostate cancer risk comparing the rs266882 GG vs AA genotypes and GA vs AA genotypes. Inverse variance weighting with a random effects model was used to create a summary estimate using the statistical package Stata (StataCorp, 2003).

RESULTS

Genotype data was available for 500 cases and 676 controls. Among cases, mean age at diagnosis was 68 years, 17% had poorly differentiated tumours (3% missing) and 31% were advanced tumour stage at diagnosis (8% missing) (Table 1). The majority of cases (71%) were diagnosed before 1992, prior to widespread PSA screening.

The rs266882 genotype distribution among controls (GG: 25%, GA: 47% and AA: 28%) was similar to other studies of white men (Xue et al., 2000; Cicek et al., 2005; Salinas et al., 2005; Sieh et al., 2006) and was in Hardy–Weinberg equilibrium (\(P = 0.18\)). Controlling for matching factors, there was no evidence of an
association between PSA genotype and total prostate cancer risk. Moreover, we found no association between the rs266882 genotype and cancer risk when we stratified within tumour grade or stage, or among those diagnosed pre/post PSA era (Table 2).

As shown earlier in Gann et al (2002), pre-diagnostic total and free PSA levels measured in baseline blood were significantly higher among cases compared with controls (Table 3). Using age-adjusted linear regression, we found no significant association between the rs266882 genotype and levels of total or free PSA among either cases or controls. Similarly, we did not see a difference in total PSA genotype and levels of total or free PSA among either cases compared with controls (Table 3). Using age-adjusted linear regression, we found no significant association between the rs266882 genotype and PSA plasma levels among cases compared with controls (Table 3). There were no significant interactions of the rs266882 genotype with PSA plasma levels. We found no association between the rs266882 genotype and prostate cancer risk among men with long or short CAG repeats. In addition, there was no evidence of modification by AR CAG repeat length on associations between the rs266882 genotype on total plasma PSA levels (P-value for interaction: controls, P = 0.80; cases, P = 0.25) and free PSA levels (controls, P = 0.30; cases, P = 0.96).

Among the 500 men with prostate cancer, 111 men died of their disease. The median survival time between diagnosis and prostate-cancer-specific death was 13.5 years (range: <1–24.3 years). We found no association between the rs266882 genotype and prostate cancer survival (Table 4).

Figure 1 presents the estimates from each of the 12 studies of the rs266882 genotype and prostate cancer risk, and the summary odds ratios from the meta-analysis. There was no evidence of an association between the GG (OR = 0.96, 95% CI: 0.77, 1.20) (Figure 1) or GA (OR = 0.92, 95% CI: 0.82, 1.03) genotypes compared with AA. Sensitivity analyses were performed by restricting the meta-analysis to eight studies conducted among predominantly white populations that reported similar rs266882 genotype distribution among controls. These analyses produced results similar to the full meta-analysis of 12 studies.

**DISCUSSION**

In this large prospective study, we comprehensively assessed the relation of the ARE1 (PSA = 158 G/A) polymorphism (rs266882 genotype) and prostate cancer risk, survival and pre-diagnostic plasma PSA levels. We found no association between the PSA polymorphism and cancer risk, overall or by grade, stage or calendar year of diagnosis. Similarly, the rs266882 genotype was not associated with cancer-specific survival. Finally, there was no association between the rs266882 genotype and PSA plasma levels among cases or controls. There were no significant interactions of the rs266882 genotype with PSA plasma level or AR CAG repeat length for any of the outcomes examined.

Given the importance of PSA, regulation of its production is of biological and clinical importance. For example, PSA cleaves insulin-like growth factor binding proteins resulting in local release of IGF-1 (Cohen et al, 1994), which has been positively associated with prostate cancer risk (Chan et al, 1998; Stattin et al, 2000). PSA has also been demonstrated to activate the small latent form of transforming growth factor-β2 (TGF-β2) (Dallas et al, 2005), one of the isoforms of TGF-β, a potent growth factor that acts as a tumour enhancer once cancer cells have become
Table 4  Hazard ratios and 95% confidence intervals of ARE1 (PSA –158 G/A) genotype and prostate cancer-specific survival, overall and stratified by grade*, stage and calendar year of diagnosis

| Study            | Cases | Controls | n  | Odds Ratio | 95% CI  |
|------------------|-------|----------|----|------------|---------|
| Severi           | 814   | 713      |    | 1.00 (Ref) | 1.00 (Ref) |
| Jesser           | 500   | 676      |    | 1.00 (Ref) | 1.00 (Ref) |
| Salinas          | 557   | 523      |    | 1.00 (Ref) | 1.00 (Ref) |
| Cicek            | 439   | 479      |    | 1.00 (Ref) | 1.00 (Ref) |
| Sieh             | 193   | 391      |    | 1.00 (Ref) | 1.00 (Ref) |
| Lai              | 209   | 223      |    | 1.00 (Ref) | 1.00 (Ref) |
| Medeiros         | 151   | 127      |    | 1.00 (Ref) | 1.00 (Ref) |
| Binnie           | 97    | 144      |    | 1.00 (Ref) | 1.00 (Ref) |
| Wang             | 300   | 266      |    | 1.00 (Ref) | 1.00 (Ref) |
| Xue              | 57    | 156      |    | 1.00 (Ref) | 1.00 (Ref) |
| Chiang           | 122   | 84       |    | 1.00 (Ref) | 1.00 (Ref) |
| Combined         |       |          |    | 1.00 (Ref) | 1.00 (Ref) |

PSA = Prostate-specific antigen. Physicians’ Health Study, 1982 –2007. *Low-grade disease: Gleason 2–6 or well differentiated; Moderate grade: Gleason 7 or moderately differentiated; High grade: Gleason 8–10 or poorly differentiated. **Hazard ratios controlled for aggressive disease (i.e., stage T3/T4 or high grade), age at diagnosis and date of diagnosis (pre/post 1992). ***Hazard ratios controlled for age at diagnosis and date of diagnosis (pre/post 1992).

Figure 1  Meta-analysis of 12 studies of the association between rs266882 GG genotype compared with AA genotype and overall prostate cancer risk. Individual and random effects, summary odds ratios and 95% confidence intervals (CI). The shaded squares and horizontal lines indicate the study-specific odds ratio and 95% CI. The diamond is the summary odds ratio and 95% CI.

Activation of TGF-β2 by PSA may potentially contribute to the formation of osteoblastic lesions in bone metastatic prostate cancer (Dallas et al, 2005).

Accordingly, numerous investigators have examined the function of rs266882 with a three-fold risk of advanced cancer (Xue et al, 2000). Subsequent studies also reported increased risk of prostate cancer with the G allele in Taiwan (122 cases, 94 controls) (Chiang et al, 2004) and Scotland (97 cases, 144 controls) (Binnie et al, 2005). A larger sibling-based case–control study (439 cases, 479 controls) (Cicek et al, 2005). A meta-analysis of 12 studies of the association between rs266882 GG genotype compared with AA genotype and overall prostate cancer risk (Siever et al, 2006) study in finding no significant association between the PSA polymorphism and risk of prostate cancer. Although, our own study cannot rule out small relative risks, taken together with our meta-analysis of the 12 studies suggests that there is no overall effect of the variant on prostate cancer risk.

Only one published study has examined the rs266882 variant with survival of prostate cancer (Severi et al, 2006). The average follow-up was 8.2 years, with 68 deaths. Our study was consistent with the Severi et al (2006) study in finding no significant association with the rs266882 genotype and risk of dying from prostate cancer.

It has been hypothesised that the rs266882 polymorphism may be associated with serum levels of PSA through higher binding affinity of the ARE1 with either the A or G allele. Results of such studies also have been contradictory. Among healthy controls (PSA levels <4 ng ml−1), higher serum PSA levels were statistically significantly associated with AA genotype when all ethnic groups were combined, but not for any of the ethnic groups individually, suggesting population stratification may be a possibility for this.

Genetics and Genomics

British Journal of Cancer (2008) 99 (10), 1743 – 1747 © 2008 Cancer Research UK
finding (Xue et al., 2001). In another study of white men with PSA levels < 4 ng ml⁻¹, men with the AA genotype had a 28% higher level of PSA than men with the GG genotype (Salinas et al., 2005). Two studies of healthy controls with PSA levels <4 ng ml⁻¹ (Rao and Cramer, 1999; Wang et al., 2003) and one with PSA < 9 ng ml⁻¹ (Severi et al., 2006) reported no association of this genotype with serum PSA level. These null results were consistent with our findings.

AR regulates PSA expression by binding androgen response elements. Some studies of AR, including ours, found shorter CAG repeats associated with increased expression of AR and with higher risk of advanced prostate cancer compared with longer CAG repeats (Giovannucci et al., 1997). Therefore, the potential interaction of the rs266882 genotype with CAG repeats in the AR is of interest. Xue et al. (2000) reported a five-fold increased risk for prostate cancer among white men with both a short CAG allele and PSA genotype GG. In the full multi-ethnic cohort, Xue et al. (2001) also reported a significant interaction (0.049) with serum PSA, which increased 7% with each decrease of one CAG among those with the AA genotype for the PSA gene. Models were adjusted for age and ethnicity, however residual confounding by ethnicity in this very diverse cohort could account for this borderline significant finding. Four additional studies, as well as the present, found no interaction between rs266882 genotype and AR CAG length in relation to plasma PSA levels (Xu et al., 2002; Rao et al., 2003; Salinas et al., 2005; Sieh et al., 2006).

The results of this large study with long-term and prospective follow-up, taken together with earlier findings and the results of the meta-analysis, add further support for the conclusion that the rs266882 polymorphism is unrelated to prostate cancer risk, survival or to plasma PSA levels.

ACKNOWLEDGEMENTS

We thank the participants of the Physicians’ Health Study for their longstanding commitment and participation in the study. The Physicians’ Health Study is supported by grants CA-34944, CA-40360 and CA-097193 from the National Cancer Institute and grants HL-26490 and HL-34595 from the National Heart, Lung and Blood Institute, Bethesda, MD. Ms Jesser was supported by the National Research Service Award Training Program in Cancer Epidemiology (T32 CA 00901). Project supported by R01 CA 09059 (NCI/NIH).

REFERENCES

(1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 321: 129 – 135

Binnie MC, Alexander FE, Heald C, Habib FK (2005) Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 63: 309 – 315

Chan JM, Stamper MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563 – 566

Chiang CH, Chen KK, Chang LS, Hong CJ (2004) The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J Urol 171: 1529 – 1532

Cicek MS, Liu X, Casey G, Witte JS (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11A1 in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14: 2173 – 2177

Cohen P, Peehl DM, Graves HC, Rosenfeld RG (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142: 407 – 415

Dallas SL, Zhao S, Cramer SD, Chen Z, Peehl DM, Bonewald LF (2005) Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 202: 361 – 370

Gann PH, Hennekens CH, Ma J, Longcope C, Stamper MJ (1996) Prospective study of serum hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118 – 1126

Gann PH, Hennekens CH, Stamper MJ (1995) A Prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273(4): 289 – 294

Gann PH, Ma J, Catalona WJ, Stamper MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 167: 2427 – 2434

Giovannucci E, Stamper MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoft PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320 – 3323

Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G, Marberger M, Vutuc C, Micksche M (2002) Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Cancerogenesis 23: 1647 – 1651

Jann OE, Palvim JJ, Kallio P, Mehto M (1993) Androgen receptor and mechanism of androgen action. Ann Med 25: 83 – 89

Lai J, Kedda MA, Hinze K, Smith RL, Yaxley J, Spurrie AB, Morris CP, Harris J, Clements JA (2007) PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Cancerogenesis 28: 1032 – 1039

Massague J (2008) TGFbeta in Cancer. Cell 134: 215 – 230

Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Carvalho R, Lopes C (2002) Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53: 88 – 94

Rao A, Chang BL, Hawkins G, Hu JJ, Rossor CJ, Hall MC, Meyers DA, Xu J, Cramer SD (2003) Analysis of CAG polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Urology 61: 864 – 869

Rao A, Cramer SD (1999) Identification of a polymorphism in the ARE1 region of the PSA promoter (abstract). Cancer Res 59: 60

Salinas CA, Austin MA, Ostrander EO, Stanford JL (2005) Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 65: 58 – 65

Schatzl G, Marberger M, Remzi M, Grosser P, Unterlehner J, Haidinger G, Zidek T, Preyer M, Micksche M, Gsur A (2005) Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer. Urology 65: 1141 – 1145

Severi G, Hayes VM, Neuring P, Padilla EJ, Tilley WD, Eggleston SA, Morris HA, English DR, Southey MG, Hopper JL, Sutherland RL, Boyle P, Giles GG (2006) Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev 15: 1142 – 1147

Sieh W, Edwards KL, Fitzpatrick AL, Srinusowanprachan SL, Farin FM, Monska SA, Kronmal RA, Eaton DL (2006) Genetic susceptibility to prostate cancer: prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control 17: 187 – 197

StatAcCorp (2003) Statistical Software: Release 8.0. College Station, TX: Stata Corporation

Stattin P, Bylund S, Rinaldi S, Biesay C, Dechau H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910 – 1917

Wang L, Sato K, Tsuchiya N, Yu JG, Ohyama C, Sato S, Habuchi T, Ogawa O, Kato T (2003) Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett 202: 53 – 59

Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, Bleeker ER, Ohar J (2002) Association studies of serum prostate specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev 11: 664 – 669

Xue W, Irvine RA, Yu MC, Ross RK, Coeetze GA, Ingles SA (2000) Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res 60: 839 – 841

Xue WM, Coeetza GA, Ross RK, Irvine R, Kolonen L, Henderson BE, Ingles SA (2001) Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol Biomarkers Prev 10: 575 – 579

© 2008 Cancer Research UK